Richard C. Zellars, MD, talks with Jean Wright, MD, about the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 trial, which evaluated the impact of tamoxifen only after breast conservation surgery for “good risk” ductal carcinoma in situ.